Eight patients (77 joints) with polyarthritis were treated systemically with 570 MBq (15.4 mCi) of rhenium 186 ((186)Re) hydroxyethylidenediphosphonate (HEDP). Pain and disease activity were assessed monthly. In six (75%) of eight patients, a single injection of (186)Re HEDP led to an improvement in disease activity. Systemic low-dose treatment with (186)Re HEDP can reduce pain and disease activity in patients with polyarthritis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1148/radiol.2211010095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ESTIMATION OF HUMAN DOSE OF 188/186RE-HEDP COCKTAIL BASED ON OLINDA/EXM AND DISTRIBUTION DATA IN RATS.
Radiat Prot Dosimetry
August 2020
Materials and Nuclear Fuel Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.
188Re and 186Re are two applicable rhenium medical radioisotopes with complementary features that make them beneficial for different sizes of tumours. The aim of this study is to investigate 188/186Re-HEDP efficacy as a cocktail by calculating absorbed radiation dose in human organs based on biodistribution data obtained by injecting it to normal rats. Three rats were sacrificed at different time intervals and the percentage of injected dose per gram of each organ was measured by direct counting from rat data.
View Article and Find Full Text PDFBone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Br J Radiol
April 2018
2 Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London , UK.
Objective: The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation in a cohort of patients with metastatic castration-resistant prostate cancer (mCRPC). The methodology for the extrapolation of the biodistribution, pharmacokinetics and absorbed doses from a given to an alternative radiopharmaceutical is presented.
Methods: Sequential single photon emission CT images from 22 patients treated with 5 GBq of Re-HEDP were used to extrapolate the time-activity curves for various radiopharmaceuticals.
Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.
Appl Radiat Isot
November 2017
Medical Physics Department, School of Medicine, Iran University of Medical Science, P.O. Box: 14155-6183, Tehran, Iran.
In this study labeling EDTMP (ethylenediamine tetra(methylene phosphonic acid)) and HEDP (Hydroxyethylidene-1, 1-Diphosphonic Acid) as the carrier ligands with Scandium-47 were investigated. The biokinetics of the bone seeking of labeled ligands with Scandium-47 were assessed by measuring the skeletal absorbed dose and then the mice data extrapolated to human absorbed dose and compared with the Rhenium-HEDP, Samarium-EDTMP dosimetry data estimated by other researchers. Because the availability of Sc was limited we performed some preliminary studies using Sc.
View Article and Find Full Text PDFIn Vitro Evaluation of Re-HEDP: A Mechanistic View of Bone Pain Palliations.
Cancer Biother Radiopharm
June 2017
1 Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India .
Skeletal metastasis is common in advanced stages of various cancers, particularly of the prostate and breast carcinoma. Re-HEDP (1-hydroxyethane 1, 1-diphosphonic acid) is a clinically established radiopharmaceutical for bone pain palliation of osseous metastasis, and it takes advantage of high bone affinity. The present work aims at elucidating the possible mechanisms of cell killing by Re-HEDP in osteosarcoma cells and biodistribution studies in mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!